MRI and advanced computer analysis bring us closer to early identification of Alzheimer’s

For the first time, scientists have captured images of brain lesions similar to those found in Alzheimer’s disease using clinical-grade MRI in an animal model of the disease, according to research reported today at the Alzheimer’s Association’s 2008 International Conference on Alzheimer’s Disease (ICAD 2008), in Chicago.

These lesions, known as amyloid plaques, have been “imaged” previously using very high power MRI scanners that are only used on animals, and also with PET scans combined with specialized marker chemicals. This is the first time images of plaques were captured with conventional, clinical strength MRI.

Two other studies reported at ICAD 2008 use MRI and advanced computer analysis to bring us closer to early identification of Alzheimer’s, perhaps even before symptoms are evident.

MRI technology is more widely distributed and relatively less expensive than other imaging technologies. In addition, it doesn’t expose people to radiation, as do the “high energy” imaging approaches.

“As we get closer to the development of therapies that can slow or even stop the progression of Alzheimer’s, earlier detection of the disease becomes crucial for early intervention,” said William Thies, PhD, vice president of Medical and Scientific Relations at the Alzheimer’s Association. “Early evaluation and diagnosis is also important because some Alzheimer’s-like symptoms can be reversed if they are caused by treatable conditions, such as depression, drug interaction, or thyroid problems. If it is Alzheimer’s, early diagnosis gives the person and their family an opportunity to build the right medical team, get access to existing medications, find helpful programs and services, and plan for the future. Plus, there is the opportunity to participate in studies of experimental drugs or other disease modifying treatments.”

“As we search for ways to identify Alzheimer’s early, these MRI studies show that researchers are moving closer to accurate early detection of the disease, and that we may soon be able to use this technology to determine who is at greater risk,” Thies added.

cells

MRI Scans Show Images of Amyloid Plaques in Rabbit Model

Definitive diagnosis of Alzheimer’s currently happens at autopsy by demonstrating the presence of characteristic brain lesions, including amyloid plaques. The ability to non-invasively show amyloid plaque levels in living people could markedly improve the diagnosis and treatment of people with Alzheimer’s.

John Ronald, a Ph.D. candidate in Medical Biophysics, along with Brian Rutt, PhD, and colleagues at the Robarts Research Institute and University of Western Ontario, London, Ontario, Canada, used clinical strength MRI scanners to take brain images from rabbits that had been fed a high cholesterol diet for more than two years. These animals form amyloid plaques in their brains.

According to the researchers, the MRI scans revealed distinct signal voids – black spots – in several brain areas including the hippocampus, which is very important for memory. Autopsy examination revealed that the void areas reflected the presence of small clusters of amyloid plaques. Each cluster had high levels of iron, which the researchers say caused the MRI signal voids; these signal voids were not found in animals fed a normal diet.

“Although some of the technology used to generate these images was designed specifically for rabbits, this preliminary discovery hints at the promise of using clinical MRI scanners to visualize plaques in people with Alzheimer’s,” Ronald said. “Extension of these technologies to living animals is practical, and should allow us to study the course of Alzheimer’s in animals over time.”

“We have customized this MRI scanner in very important ways for microimaging. Particularly, we have added special hardware that allows the scanner to clearly detect structures smaller than 50 microns (0.05 mm) and to more sensitively detect iron-containing structures than has been possible using clinical MRI in the past,” Ronald added.

Computer Analysis of MRI Scans Gives Alzheimer’s Disease Severity “Score”

In addition to amyloid plaques, there is another brain lesion that is characteristic of Alzheimer’s – neurofibrillary tangles. The “gold standard” for post mortem measurement of Alzheimer’s tangle severity is known as Braak staging.

Prashanthi Vemuri, PhD, Clifford R. Jack, MD, and colleagues at the Mayo Clinic, Rochester, MN, sought to validate the ability of a new MRI analysis algorithm – known as the STructural Abnormality iNDex (STAND) score – to capture Alzheimer’s-related tangle severity. This was done by comparing the person’s STAND-score derived from an MRI scan taken before death with the person’s Braak stage calculated after death.

The researchers developed an algorithm that extracts atrophy information from an individual patient’s three-dimensional MRI scan. A STAND-score is assigned based on comparing the degree of atrophy in the person’s brain to atrophy patterns extracted from a large library of 160 Alzheimer’s and 160 cognitively normal subjects’ MRI scans. The STAND score is positive if the brain looks more Alzheimer’s-like and negative if the scan looks normal, and can be adjusted for demographics. According to the researchers, STAND-scores have 90 percent accuracy in distinguishing the MRI scans of people with Alzheimer’s from normal MRI scans.

In order to verify the adjusted STAND scores against Braak staging, the researchers identified 101 patients who had an MRI scan within four years of the time of death as well as postmortem Braak staging. They compared the two and, on a scale of 0 to 1, found the strength of association between the STAND-score and Braak stage to be 0.63 (p<0.0001).

“This study shows that information extracted from MRI scans can accurately capture the severity of Alzheimer’s tangle pathology,” said Vemuri. “While this work needs to be replicated and confirmed, because there is evidence indicating that structural changes in the brain precede cognitive symptoms, STAND scores may also prove to be useful for early identification of Alzheimer’s.”

MRI Used to Measure Alzheimer-like Patterns of Brain Atrophy in Normal Elderly

In previously reported research, Christos Davatzikos, PhD, of the Department of Radiology at the University of Pennsylvania, Philadelphia; Susan Resnick, PhD, of the National Institute on Aging, Bethesda, MD; and colleagues used a new computer-based image analysis technique (advanced high-dimensional pattern classification) to analyze MRI scans from participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and to derive an index of Alzheimer-like brain abnormality.

In a new study reported at ICAD 2008, they examined the presence and progression of such patterns in elderly individuals who are cognitively normal, and a small group with mild cognitive impairment (MCI), from the Baltimore Longitudinal Study of Aging (BLSA).

One hundred nine (109) healthy elderly participants from the BLSA were analyzed over periods of up to nine years. The researchers found that Alzheimer’s-like patterns of brain atrophy were increasingly present in participants over age 80. The rate of progression of the index of Alzheimer- like patterns over time also was higher in the older participants. Memory performance of healthy elderly and those with MCI who displayed Alzheimer-like brain atrophy patterns, as measured using standard neuropsychological batteries, was lower compared to people that didn’t display these patterns and had lower Alzheimer-like index values.

“Although the clinical significance of these Alzheimer’s-like patterns of brain atrophy must be further evaluated, we are very hopeful that these pattern analysis tools will provide early indicators of brain changes that resemble those seen in people with Alzheimer’s, years before memory problems are recognized clinically,” said Davatzikos.

* John Ronald – “Direct visualization of Beta-amyloid plaques in hypercholesterolemic rabbits using clinical field-strength MRI.” (Funders: Heart and Stroke Foundation of Canada, Canadian Institutes for Health Research, National Institutes of Health (NHLBI))

* Prashanthi Vemuri – “Antemortem MRI based structural abnormality index (STAND)-scores correlate with postmortem Alzheimer disease Braak stages.” (Funders: National Institute on Aging, Robert H. and Clarice Smith and Abigail Van Buren Alzheimer’s Disease Research Program, Alexander Family Professorship of the Mayo Foundation)

* Christos Davatzikos, Susan Resnick – “Longitudinal progression of Alzheimer’ disease-like patterns of brain atrophy in normal elderly MCI diagnosis.” (Funders: National Institute on Aging, Institute for the Study of Aging)

Source: Alzheimer’s Association


Nexavar Approved for Liver Cancer in China

  • Author: Health Informer
  • Filed under: Health News
  • Date: Jul 28,2008

First and only drug therapy to address major Chinese health concern

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that the State Food and Drug Administration (SFDA) of China has approved Nexavar(R) (sorafenib) tablets for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC), or liver cancer. Nexavar is the first and only oral targeted therapy to significantly improve overall survival in patients with the disease.

The approval was based on two international Phase 3 double-blind, placebo-controlled trials that evaluated more than 800 patients who received no prior systemic therapy.

“China has the highest number of liver cancer patients worldwide with more than 340,000 new cases diagnosed each year and the incidence is continuing to rise,” said Gunnar Riemann, PhD, member of the Executive Committee of Bayer HealthCare. “We are proud to be at the forefront of liver cancer treatment with Nexavar and are hopeful that patients in China can potentially have their lives extended by treatment with Nexavar.”

“This is another significant milestone in a region where patients are in dire need of a therapy that improves survival,” said N. Anthony Coles, MD, president and chief executive officer, Onyx Pharmaceuticals, Inc. “The approval in liver cancer in China comes less than two years after the approval in advanced kidney cancer and proves that Nexavar is and will continue to be an important foundational therapy in multiple patient populations.”

Hepatocellular carcinoma is the most common form of liver cancer and is responsible for about 90 percent of the primary malignant liver tumors in adults. Liver cancer is the sixth most common cancer in the world and the third leading cause of cancer-related deaths globally. More than 600,000 cases of liver cancer are diagnosed worldwide each year (more than 400,000 in China, South Korea, Japan and Taiwan, 54,000 in the European Union, and 15,000 in the United States) and the incidence is increasing. In 2002, approximately 600,000 people died of liver cancer including approximately 370,000 in China, South Korea and Japan, 57,000 in the European Union, and 13,000 in the United States.(1)(2)

In the Asia-Pacific region, more than eight percent of the general population is infected with chronic hepatitis B and between two and four percent is infected with chronic hepatitis C.(3)(4) Both infections are the leading causes of primary liver cancer worldwide.

Nexavar’s Differentiated Mechanism

Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has been shown to target members of two classes of kinases known to be involved in both cell proliferation (growth) and angiogenesis (blood supply) — two important processes that enable cancer growth. These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-B, KIT, FLT-3 and RET. Preclinical models have also demonstrated that Raf/MEK/ERK has a role in HCC; therefore blocking signaling through Raf-1 may offer therapeutic benefits in HCC.

Nexavar is currently approved in more than 40 countries for liver cancer and in more than 70 countries for the treatment of patients with advanced kidney cancer. Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators as a single agent or combination treatment in a wide range of cancers, including metastatic melanoma, lung cancer, breast cancer and as an adjuvant therapy for kidney cancer.

Important Safety Considerations For Patients Taking Nexavar

Based on the currently approved U.S. package insert for the treatment of patients with unresectable hepatocellular carcinoma, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed. Bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo. The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo. Most common adverse events reported with Nexavar in patients with unresectable HCC were diarrhea, fatigue, abdominal pain, weight loss, anorexia, nausea and hand-foot skin reaction. Grade 3/4 adverse events were 45% for Nexavar vs. 32% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

For information about Nexavar including U.S. Nexavar prescribing information, visit http://www.nexavar.com/ or call 1.866.NEXAVAR (1.866.639.2827).

(1) Ferlay J, et al., GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No.5, Version 2.0. IARCPress, Lyon, 2004. Available at: http://www-dep.iarc.fr/. Accessed May 2008.

(2) 2005 Cancer Register System (CRS) annual report, http://crs.cph.ntu.edu.tw/crs_c/annual.html. Accessed May 12, 2008.

(3) World Health Organization, Fact Sheet N 164, October 2000. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed May 2008.

(4) Stanford University School of Medicine, Asian Liver Center, “FAQ About Hepatitis B,” February 2008. http://liver.stanford.edu/Education/faq.html. Accessed May 2008.

Source: Bayer HealthCare Pharmaceuticals; Onyx Pharmaceuticals, Inc.


Controlling Blood Pressure Helps Keep Hearts Healthy

Philadelphia-High blood pressure, also known as hypertension, affects nearly one in three adults in the United States. Dubbed the “silent killer” because of its lack of outward symptoms, high blood pressure can begin during childhood and lead to serious complications later in life, including heart disease, stroke, and kidney failure. But with regular doctor visits and important lifestyle changes, blood pressure can be kept under control and serious complications can be avoided.

Blood pressure is an essential part of the circulatory system, helping blood to move through the body, bringing oxygen and nutrients to vital organs. High blood pressure can put stress on the system and cause major health problems.

Blood pressure is broken down into two readings. The first reading is the pressure when the heart is beating. This is called the systolic pressure. The second reading is the pressure between beats, when the heart is at rest. This is called the diastolic pressure. A healthy blood pressure reading for an adult should be less than 120 mm systolic pressure and less than 80 mm diastolic pressure (120/80 mm) or as doctors will say, “120 over 80.”

High blood pressure does not have to lead to serious complications. If you have high blood pressure, your doctor can recommend healthy habits to keep your condition under control.

blood-presure

blood-presure

Tips for keeping blood pressure down:
• Exercise regularly and maintain a healthy weight
• Have a low-salt, low-fat diet
• Eat plenty of fruits, vegetables and whole grain foods
• Quit smoking and limit alcohol use
• Reduce stress through meditation
• Limit caffeine
• Take BP medication daily if prescribed by your doctor

About Health Partners:
Founded in 1985, Health Partners is the result of a unique collaboration among seven area hospitals to create a not-for-profit health plan for residents of Philadelphia. Over more than 20 years, Health Partners has garnered national attention for innovations in managed care, and now serves 140,000 members throughout southeastern Pennsylvania.


Healthation, a healthcare technology company, announced that it has signed a 10-year Software as a Service agreement with Health Partners, a not-for-profit health plan serving more than 140,000 members in southeastern Pennsylvania. Health Partners will implement AboveHealth(R), the industry leading, e-business healthcare portal to deliver interactive, real-time communication and administration capabilities to its provider community.

With the AboveHealth portal, Health Partners will empower physicians and their staff with increased efficiency while reducing costs. Important to Health Partners is the 24-hour a day interaction healthcare professionals will have with their health plan. Hal Augustine, CIO of Health Partners said, “We are truly excited about our new relationship and look forward to working together to meet our goals for further enhancing our providers’ experience with significantly advanced self-service capabilities.”

“Health Partners shares our vision for a transformed retail healthcare marketplace,” said Scott Kornhauser, CEO of Healthation. “We look forward to playing a role in their innovative market advancement.”

Healthation’s AboveHealth Self Service Web Portal is an integrated Web portal solution supporting a payer’s Web self-service and automated e-business strategies. Clients can use the AboveHealth rules-driven interface to configure everything from branding and forms management to workflow…all down to the group or line of business.

About Health Partners

Founded in 1985, Health Partners is the result of a unique collaboration among seven area hospitals to create a not-for-profit health plan for residents of Philadelphia. Over more than 20 years, Health Partners has garnered national attention for innovations in managed care, and now serves more than 140,000 members throughout southeastern Pennsylvania. Please visit us at www.healthpart.com.

About Healthation

Darien, IL- based Healthation is a healthcare technology company helping payers and administrators improve business performance with user-driven rules-based benefits management and transaction processing solutions. Healthation’s goal is to accelerate a retail transformation in healthcare with a real-time, open exchange platform. The company’s AcceleHealth(R) solution is the industry’s only web-based payer system built to administer benefits in real-time across all lines of business under one master member record including medical, dental, vision, pharmacy, life and AD&D.

Source: Health Partners